Table 2.
Treatment | Number of studies | Pooled number of patients | Pooled median PFS | Accuracy interval | Bootstrap estimated 95% confidence limits |
---|---|---|---|---|---|
Any line of therapy | |||||
Single-agent erlotinib | 26 | 731 | 12.4 | 11.6–13.4 | 10.9–13.4 |
Single-agent gefitinib | 54 | 1802 | 9.4 | 9.0–9.8 | 8.7–10.2 |
Chemotherapy | 20 | 984 | 5.6 | 5.3–6.0 | 5.1–6.2 |
Predominantly first line* | |||||
Single-agent erlotinib | 10 | 354 | 12.0 | 10.8–13.3 | 10.8–13.1 |
Single-agent gefitinib | 16 | 703 | 9.8 | 9.1–10.5 | 9.0–10.6 |
Chemotherapy | 17 | 868 | 5.8 | 5.5–6.2 | 5.4–6.4 |
Lines of therapy other than first | |||||
Single-agent erlotinib | 17 | 377 | 12.9 | 11.6–14.3 | 10.0–13.9 |
Single-agent gefitinib | 37 | 1099 | 9.2 | 8.6–9.7 | 8.3–10.5 |
Chemotherapy | 3 | 116 | 4.1 | 3.5–5.0 | n/a† |
Predominantly first line is ≥90% of patients treated in the first-line setting.
Because of the low number of studies in this pool the bootstrap estimate is not trustworthy.